S&P 500   3,224.64 (+0.85%)
DOW   26,851.18 (+0.78%)
QQQ   260.31 (-0.02%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,224.64 (+0.85%)
DOW   26,851.18 (+0.78%)
QQQ   260.31 (-0.02%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,224.64 (+0.85%)
DOW   26,851.18 (+0.78%)
QQQ   260.31 (-0.02%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,224.64 (+0.85%)
DOW   26,851.18 (+0.78%)
QQQ   260.31 (-0.02%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
Log in

CVE:ICOiCo Therapeutics Stock Price, Forecast & News

C$0.04
-0.01 (-11.11 %)
(As of 07/15/2020 12:12 PM ET)
Add
Compare
Today's Range
C$0.04
Now: C$0.04
C$0.04
50-Day Range
C$0.04
MA: C$0.05
C$0.06
52-Week Range
C$0.02
Now: C$0.04
C$0.15
Volume15,000 shs
Average Volume500,087 shs
Market CapitalizationC$6.15 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-6029414

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.01 per share
Book ValueC$0.00 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$6.15 million
Next Earnings Date8/26/2020 (Estimated)
OptionableNot Optionable

Receive ICO News and Ratings via Email

Sign-up to receive the latest news and ratings for ICO and its competitors with MarketBeat's FREE daily newsletter.

iCo Therapeutics (CVE:ICO) Frequently Asked Questions

How has iCo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

iCo Therapeutics' stock was trading at C$0.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ICO shares have decreased by 11.1% and is now trading at C$0.04. View which stocks have been most impacted by Coronavirus.

When is iCo Therapeutics' next earnings date?

iCo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020. View our earnings forecast for iCo Therapeutics.

How were iCo Therapeutics' earnings last quarter?

iCo Therapeutics Inc (CVE:ICO) issued its quarterly earnings results on Friday, May, 15th. The company reported ($0.01) earnings per share for the quarter. View iCo Therapeutics' earnings history.

Has iCo Therapeutics been receiving favorable news coverage?

News coverage about ICO stock has trended extremely negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. iCo Therapeutics earned a media sentiment score of -4.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the stock's share price in the near future. View the latest news about iCo Therapeutics.

Who are some of iCo Therapeutics' key competitors?

What other stocks do shareholders of iCo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCo Therapeutics investors own include iCo Therapeutics (ICOTF), Theratechnologies (TH), Regulus Therapeutics (RGLS), Nemaska Lithium (NMX), Freeport-McMoRan (FCX), Eldorado Gold (EGO), Dextera Surgical (DXTR), Aurora Cannabis (ACBFF) and Aurora Cannabis (ACB).

Who are iCo Therapeutics' key executives?

iCo Therapeutics' management team includes the following people:
  • Mr. Andrew J. Rae M.B.A., BSc, MBA, Co-Founder, CEO, Pres & Director (Age 52)
  • Mr. Michael Liggett CPA, CA, Bsc. Pharm., CFO, Corp. Sec. & Director (Age 59)
  • Dr. Peter Hnik M.D., MHSc, Chief Medical Officer (Age 63)

What is iCo Therapeutics' stock symbol?

iCo Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ICO."

How do I buy shares of iCo Therapeutics?

Shares of ICO and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is iCo Therapeutics' stock price today?

One share of ICO stock can currently be purchased for approximately C$0.04.

How big of a company is iCo Therapeutics?

iCo Therapeutics has a market capitalization of C$6.15 million.

What is iCo Therapeutics' official website?

The official website for iCo Therapeutics is www.icotherapeutics.com.

How can I contact iCo Therapeutics?

iCo Therapeutics' mailing address is 760-777 Hornby St, VANCOUVER, BC V6Z 1S4, Canada. The company can be reached via phone at +1-604-6029414.

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.